mProX™ Human SIGLEC9 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SIGLEC9 (sialic acid-binding immunoglobulin-like lectin 9) has several applications. In patients with severe fever with thrombocytopenia syndrome (SFTS), the decreased expression of SIGLEC9 on natural killer (NK) cells predicts NK cell dysfunction, suggesting that SIGLEC9 may be a potential marker for functional NK cell subsets in SFTS patients. In hepatocellular carcinoma (HCC), DHRS1 (a gene associated with SIGLEC9) is a potential predictor of HCC and a promising prognostic biomarker. In macrophages, N-glycan processing, which regulates macrophage effector function, affects antibody-dependent cellular phagocytosis (ADCP). SIGLEC9 is one of the immune receptors that correlates with increased ADCP. In atherosclerotic plaque instability, SIGLEC9 is one of the NET-related genes that may identify unstable plaques and prevent complications of plaque disruption. In high-grade serous ovarian cancer (HGSC), SIGLEC9 is predominantly expressed on tumor-associated macrophages (TAMs) and is associated with an immunosuppressive phenotype. SIGLEC9+TAMs may serve as an independent prognostic marker for poor survival and a predictive biomarker for anti-PD-1/anti-programmed death ligand-1 immunotherapy in HGSC. The potential of targeting SIGLEC9+TAMs as a therapeutic strategy is worth exploring.